Nucleic Acid Therapeutics Market (By Products: Anti-sense Oligonucleotides (ASOs) and DNA Aptamers, RNA Interference [RNAi] and Short Interfering RNAs [siRNAs], Others; By Application: Monogenetic Disorders, Multi-Genetic Disorders; By End User: Hospitals and Clinics, Academic and Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Nucleic Acid Therapeutics Market
5.1. COVID-19 Landscape: Nucleic Acid Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Nucleic Acid Therapeutics Market, By Products
8.1. Nucleic Acid Therapeutics Market Revenue and Volume, by Products, 2024-2033
8.1.1 Anti-sense Oligonucleotides (ASOs) and DNA Aptamers
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. RNA Interference [RNAi] and Short Interfering RNAs [siRNAs]
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
8.1.3. Others
8.1.3.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 9. Global Nucleic Acid Therapeutics Market, By Application
9.1. Nucleic Acid Therapeutics Market Revenue and Volume, by Application, 2024-2033
9.1.1. Monogenetic Disorders
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Multi-Genetic Disorders
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 10. Global Nucleic Acid Therapeutics Market, By End User
10.1. Nucleic Acid Therapeutics Market Revenue and Volume, by End User, 2024-2033
10.1.1. Hospitals and Clinics
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. Academic and Research Institutes
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 11. Global Nucleic Acid Therapeutics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.1.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.1.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.1.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.1.4.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.1.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.1.5.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.2.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.2.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.2.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.2.4.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.2.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.2.5.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.2.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.2.6.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.2.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.2.7.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.3.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.3.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.3.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.3.4.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.3.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.3.5.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.3.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.3.6.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.3.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.3.7.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.4.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.4.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.4.4.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.4.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.4.5.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.4.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.4.6.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.4.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.4.7.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.5.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.5.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.5.4.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Products (2021-2033)
11.5.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)
11.5.5.3. Market Revenue and Volume Forecast, by End User (2021-2033)
Chapter 12. Company Profiles
12.1. Genzyme
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Sanofi
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Piezo Therapeutics
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Transcode Therapeutics
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. NOVARTIS AG.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Aldevron
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Switch Therapeutics
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Sarpeta Therapeutics
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Qaigen NV
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Impilo Therapeutics
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client